STOCK TITAN

[SCHEDULE 13G/A] 2seventy bio, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

The reporting persons — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin — submitted a Schedule 13G/A with respect to 2seventy bio, Inc.'s common stock. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest and reports zero shares and 0% ownership. The cover information lists reporting-person classifications including IA, OO, PN, HC, and IN.

The filing contains certifications that the securities were acquired and are held in the ordinary course of business and were not acquired to influence control. The submission states no sole or shared voting or dispositive power for any reporting person and attaches Exhibit 99.1 (agreement regarding joint filing).

I soggetti dichiaranti — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP e David A. Witkin — hanno presentato un Schedule 13G/A relativo alle azioni ordinarie di 2seventy bio, Inc.. Ciascun dichiarante rinuncia alla titolarità beneficiaria, salvo per l'eventuale interesse pecuniario, e indica zero azioni e una partecipazione pari allo 0%. Le informazioni di copertina elencano le classificazioni dei soggetti dichiaranti, tra cui IA, OO, PN, HC e IN.

La documentazione contiene certificazioni che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attività e non sono stati acquisiti per influenzare il controllo. La dichiarazione precisa che nessun dichiarante esercita poteri di voto o di disposizione in via esclusiva o congiunta e allega Exhibit 99.1 (accordo relativo alla presentazione congiunta).

Los sujetos informantes — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP y David A. Witkin — presentaron un Schedule 13G/A respecto a las acciones ordinarias de 2seventy bio, Inc.. Cada sujeto informante renuncia a la titularidad beneficiaria salvo en la medida de cualquier interés pecuniario y declara cero acciones y 0% de participación. La información de portada enumera las clasificaciones de los sujetos informantes, incluyendo IA, OO, PN, HC y IN.

El expediente contiene certificaciones de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no se adquirieron para influir en el control. La presentación indica que ninguno de los informantes tiene poder de voto o de disposición, ni en forma exclusiva ni compartida, y adjunta Exhibit 99.1 (acuerdo sobre la presentación conjunta).

보고인들 — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LPDavid A. Witkin — 은 2seventy bio, Inc.의 보통주에 관해 Schedule 13G/A를 제출했습니다. 각 보고인은 금전적 이익이 있는 경우를 제외하고 실질적 소유권을 부인하며 보유 주식 수 0주 및 소유 비율 0%를 보고합니다. 표지 정보에는 보고인 분류로 IA, OO, PN, HCIN 등이 기재되어 있습니다.

해당 제출서에는 증권이 통상적인 영업 과정에서 취득되어 보유되고 있으며 지배권에 영향을 미치기 위해 취득된 것이 아님을 인증하는 내용이 포함되어 있습니다. 제출서에는 어떤 보고인도 단독 또는 공동의 의결권이나 처분권을 보유하지 않음을 명시하고 Exhibit 99.1(공동 제출에 관한 합의서)을 첨부하고 있습니다.

Les déclarants — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP et David A. Witkin — ont déposé un Schedule 13G/A concernant les actions ordinaires de 2seventy bio, Inc.. Chaque déclarant décline la qualité de propriétaire effectif, sauf dans la mesure d'un intérêt pécuniaire éventuel, et déclare zéro action et 0% de participation. Les informations de couverture indiquent les classifications des déclarants, notamment IA, OO, PN, HC et IN.

Le dossier contient des attestations selon lesquelles les titres ont été acquis et sont détenus dans le cours normal de l'activité et n'ont pas été acquis pour influer sur le contrôle. La soumission précise qu'aucun déclarant ne détient de pouvoir de vote ou de disposition exclusif ou conjoint et joint Exhibit 99.1 (accord relatif au dépôt conjoint).

Die meldenden Personen — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP und David A. Witkin — haben ein Schedule 13G/A in Bezug auf die Stammaktien von 2seventy bio, Inc. eingereicht. Jede meldende Person weist eine wirtschaftliche Eigentümerschaft, soweit nicht ein pecuniäres Interesse besteht, zurück und meldet null Aktien und 0% Beteiligung. Die Deckblattangaben listen Meldungsklassifikationen wie IA, OO, PN, HC und IN auf.

Die Einreichung enthält Bestätigungen, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zwecke der Einflussnahme auf die Kontrolle erworben wurden. Die Einreichung erklärt, dass keine meldende Person alleinige oder gemeinsame Stimm- oder Verfügungsgewalt besitzt, und fügt Exhibit 99.1 (Vereinbarung zur gemeinsamen Einreichung) bei.

Positive
  • Clear disclosure that each reporting person holds 0 shares (0%) of the issuer's common stock
  • Certifications stating securities were acquired and are held in the ordinary course of business
  • Attachment of Exhibit 99.1 documenting the agreement regarding joint filing, supporting transparency
Negative
  • None.

Insights

TL;DR: Beryl and affiliates report no economic or voting interest in 2seventy bio; this filing is informational and has no effect on the cap table.

The Schedule 13G/A discloses 0 shares (0%) beneficially owned by each named reporting person and confirms no sole or shared voting/dispositive powers. From a market-impact perspective, the filing conveys no change to ownership concentration or potential activism risk. The certifications that holdings are in the ordinary course further indicate this is a routine disclosure rather than a strategic acquisition or control attempt.

TL;DR: No reported ownership or control rights by the filers; governance and shareholder structure remain unchanged.

The document includes explicit disclaimers that the filers do not claim beneficial ownership beyond pecuniary interest and shows no voting or dispositive authority. The attached joint-filing agreement (Exhibit 99.1) documents coordination on the filing but does not reflect share accumulation. For governance analysis, there are no new shareholder nominees, control assertions, or changes to board voting dynamics arising from this filing.

I soggetti dichiaranti — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP e David A. Witkin — hanno presentato un Schedule 13G/A relativo alle azioni ordinarie di 2seventy bio, Inc.. Ciascun dichiarante rinuncia alla titolarità beneficiaria, salvo per l'eventuale interesse pecuniario, e indica zero azioni e una partecipazione pari allo 0%. Le informazioni di copertina elencano le classificazioni dei soggetti dichiaranti, tra cui IA, OO, PN, HC e IN.

La documentazione contiene certificazioni che i titoli sono stati acquisiti e sono detenuti nell'ordinario svolgimento dell'attività e non sono stati acquisiti per influenzare il controllo. La dichiarazione precisa che nessun dichiarante esercita poteri di voto o di disposizione in via esclusiva o congiunta e allega Exhibit 99.1 (accordo relativo alla presentazione congiunta).

Los sujetos informantes — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP y David A. Witkin — presentaron un Schedule 13G/A respecto a las acciones ordinarias de 2seventy bio, Inc.. Cada sujeto informante renuncia a la titularidad beneficiaria salvo en la medida de cualquier interés pecuniario y declara cero acciones y 0% de participación. La información de portada enumera las clasificaciones de los sujetos informantes, incluyendo IA, OO, PN, HC y IN.

El expediente contiene certificaciones de que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no se adquirieron para influir en el control. La presentación indica que ninguno de los informantes tiene poder de voto o de disposición, ni en forma exclusiva ni compartida, y adjunta Exhibit 99.1 (acuerdo sobre la presentación conjunta).

보고인들 — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LPDavid A. Witkin — 은 2seventy bio, Inc.의 보통주에 관해 Schedule 13G/A를 제출했습니다. 각 보고인은 금전적 이익이 있는 경우를 제외하고 실질적 소유권을 부인하며 보유 주식 수 0주 및 소유 비율 0%를 보고합니다. 표지 정보에는 보고인 분류로 IA, OO, PN, HCIN 등이 기재되어 있습니다.

해당 제출서에는 증권이 통상적인 영업 과정에서 취득되어 보유되고 있으며 지배권에 영향을 미치기 위해 취득된 것이 아님을 인증하는 내용이 포함되어 있습니다. 제출서에는 어떤 보고인도 단독 또는 공동의 의결권이나 처분권을 보유하지 않음을 명시하고 Exhibit 99.1(공동 제출에 관한 합의서)을 첨부하고 있습니다.

Les déclarants — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP et David A. Witkin — ont déposé un Schedule 13G/A concernant les actions ordinaires de 2seventy bio, Inc.. Chaque déclarant décline la qualité de propriétaire effectif, sauf dans la mesure d'un intérêt pécuniaire éventuel, et déclare zéro action et 0% de participation. Les informations de couverture indiquent les classifications des déclarants, notamment IA, OO, PN, HC et IN.

Le dossier contient des attestations selon lesquelles les titres ont été acquis et sont détenus dans le cours normal de l'activité et n'ont pas été acquis pour influer sur le contrôle. La soumission précise qu'aucun déclarant ne détient de pouvoir de vote ou de disposition exclusif ou conjoint et joint Exhibit 99.1 (accord relatif au dépôt conjoint).

Die meldenden Personen — Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP und David A. Witkin — haben ein Schedule 13G/A in Bezug auf die Stammaktien von 2seventy bio, Inc. eingereicht. Jede meldende Person weist eine wirtschaftliche Eigentümerschaft, soweit nicht ein pecuniäres Interesse besteht, zurück und meldet null Aktien und 0% Beteiligung. Die Deckblattangaben listen Meldungsklassifikationen wie IA, OO, PN, HC und IN auf.

Die Einreichung enthält Bestätigungen, dass die Wertpapiere im gewöhnlichen Geschäftsverlauf erworben und gehalten werden und nicht zum Zwecke der Einflussnahme auf die Kontrolle erworben wurden. Die Einreichung erklärt, dass keine meldende Person alleinige oder gemeinsame Stimm- oder Verfügungsgewalt besitzt, und fügt Exhibit 99.1 (Vereinbarung zur gemeinsamen Einreichung) bei.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Beryl Capital Management LLC
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer
Date:07/31/2025
Beryl Capital Management LP
Signature:/s/ Andrew Nelson
Name/Title:Chief Operating Officer of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP
Date:07/31/2025
Beryl Capital Partners II LP
Signature:/s/ Andrew Nelson
Name/Title:COO of Beryl Capital Management LLC, General Partner of Beryl Capital Management LP, General Partner of Beryl Capital Partners II LP
Date:07/31/2025
David A. Witkin
Signature:/s/ David A. Witkin
Name/Title:Reporting person
Date:07/31/2025
Exhibit Information

Exhibit 99.1 - Agreement Regrding Joint Filing of Statement on Schedule 13D or 13G

FAQ

How many shares of 2seventy bio (TSVT) do the reporting persons own?

The filing reports 0 shares beneficially owned by each reporting person, representing 0% of the class.

Which entities and individuals filed the Schedule 13G/A for TSVT?

The filing was made by Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP, and David A. Witkin.

Do the filers claim voting or dispositive power over TSVT shares?

No. The schedule reports no sole or shared voting power and no sole or shared dispositive power for any reporting person.

Does this Schedule 13G/A indicate an attempt to influence control of 2seventy bio?

No. The certifications state the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control.

Is there any agreement or exhibit attached to the filing?

Yes. The filing references Exhibit 99.1, an agreement regarding the joint filing of the statement.
2Seventy Bio

NASDAQ:TSVT

TSVT Rankings

TSVT Latest News

TSVT Latest SEC Filings

TSVT Stock Data

266.14M
49.56M
6.59%
85.1%
9.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE